Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase I randomized placebo-controlled ascending-dose study of GDC-0134 in amyotrophic lateral sclerosis
NL-OMON46547Phase 1Active, not recruiting
- Sponsor
- Genentech
- Start
- Aug 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of GDC-0134 in amyotrophic lateral sclerosis (ALS), sponsored by Genentech. Primary endpoint: Incidence, nature, and severity of all adverse events. Started Aug 2018; status: active, not recruiting.
02
Drugs
GDC-0134
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NL-OMON46547.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON46547.